Evidence map›Paper›PMID 32947131›Full record

ReviewCurrent opinion in immunology2020

Infection and cancer suppress pDC derived IFN-I.

Trever T Greene, Yea-Ra Jo, Elina I Zuniga

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Tumor Immune Microenvironment in Breast Cancer Progression.Acta oncologica (Stockholm, Sweden) · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Trever T GreeneUniversity of California San Diego, Department of Biological Sciences, San Diego, United States.
Yea-Ra JoUniversity of California San Diego, Department of Biological Sciences, San Diego, United States.
Elina I ZunigaUniversity of California San Diego, Department of Biological Sciences, San Diego, United States. Electronic address: eizuniga@ucsd.edu.
University of California San Diego · USUniversity of San Diego · US

Funding

Single-Cell Transcriptomic and Epigenetics CoreP01AI132122 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2018 to 2022
$9.8M
Inhibitory Pathways Underlying Viral Persistence In VivoR01AI081923 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Elina I Zuniga · 2009 to 2026
$6.6M
Positive Immune-regulators During Chronic Viral InfectionsR01AI113923 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2015 to 2024
$5.1M
Molecular Mechanisms Underlying Dendritic Cell Adaptations During Chronic InfectionR01AI145314 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZUNIGA, ELINA I · 2020 to 2024
$2.4M
NIAID NIH HHS P01 AI132122NIAID NIH HHS R01 AI081923NIAID NIH HHS R01 AI113923NIAID NIH HHS R01 AI145314
6 · The paper itself

Abstract

Plasmacytoid dendritic cells (pDCs) are specialized producers of Type I interferon (IFN-I) that promote anti-viral and anti-tumor immunity. However, chronic infections and cancer inhibit pDC-derived IFN-I. While the mechanisms of this inhibition are multifarious they can be classified broadly into two categories: i) reduction or ablation of pDC IFN-I-production capacity (functional exhaustion) and/or ii) decrease in pDC numbers (altered population dynamics). Recent work has identified many processes that contribute to suppression of pDC-derived IFN-I during chronic infections and cancer, including sustained stimulation through Toll Like Receptors (TLRs), inhibitory microenvironments, inhibitory receptor ligation, and reduced development from bone marrow progenitors and apoptosis. Emerging success leveraging pDCs in treatment of disease through TLR activation illustrates the therapeutic potential of targeting pDCs. Deeper understanding of the systems that limit pDC-derived IFN-I has the potential to improve these emerging therapies as well as help devising new approaches that harness the outstanding IFN-I-production capacity of pDCs.

Indexed as

Dendritic CellsHumansInfectionsInterferon-alphaNeoplasmsInterferon-alpha

Identifiers

PMID32947131
PMCPMC8526282
OpenAlexW3087672637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.